Zoetis ( (ZTS) ) has released its Q3 earnings. Here is a breakdown of the information Zoetis presented to its investors.
Zoetis Inc., a leading animal health company, is renowned for its commitment to advancing animal care through its diverse portfolio of medicines, vaccines, and diagnostic products for companion animals and livestock, operating across over 100 countries.
In its third-quarter 2024 earnings report, Zoetis announced impressive results, with a revenue increase of 11% to $2.4 billion and a net income rise of 14% to $682 million, driven by strong growth in both the U.S. and international markets. The company also raised its full-year 2024 revenue guidance, reflecting its robust performance and strategic focus.
Key financial highlights include a 15% revenue growth in the U.S. and 13% operational revenue growth internationally, with companion animal products showing significant gains. The company’s adjusted net income reached $716 million, marking a 15% operational increase. Zoetis’s investments in innovation, including new product approvals in international markets, further underline its growth strategy.
Looking ahead, Zoetis is optimistic about its continued growth, raising its full-year revenue guidance to between $9.2 billion and $9.3 billion, with an expected operational growth in adjusted net income between 13.5% and 14.5%, emphasizing its strong market position and strategic execution.
